)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Toleranzia
Toleranzia (TOL) investor relations material
Toleranzia has been acquired by Flerie
Toleranzia Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Operating loss widened to SEK -2,835 thousand for Q2 and SEK -6,128 thousand for H1 2025, reflecting increased R&D and merger-related costs.
Extraordinary General Meeting approved merger with Flerie AB; delisting from Nasdaq First North Growth Market expected August 18, 2025.
SEK 20 million credit facility secured from Flerie AB to support clinical trial preparations and ongoing operations.
Focus remains on advancing TOL2 for myasthenia gravis and TOL3 for ANCA vasculitis, with clinical trial preparations ongoing.
Financial highlights
Q2 operating loss: SEK -2,835 thousand (vs. -1,788 thousand Q2 2024); H1 operating loss: SEK -6,128 thousand (vs. -3,429 thousand H1 2024).
Cash flow from operating activities: SEK -3,978 thousand in Q2 (vs. -40 thousand Q2 2024); SEK -7,168 thousand in H1 (vs. -3,699 thousand H1 2024).
Investments in intangible assets: SEK 4,073 thousand in Q2 (vs. 7,414 thousand Q2 2024); SEK 9,244 thousand in H1 (vs. 12,101 thousand H1 2024).
Cash and bank balances at June 30: SEK 2,366 thousand (vs. 2,293 thousand June 2024).
Earnings per share: SEK -0.01 for Q2 (vs. 0.01 Q2 2024); SEK -0.02 for H1 (vs. 0.01 H1 2024).
Outlook and guidance
Clinical trial for TOL2 will not commence without full financing; additional capital injections required.
Upon merger completion, operations will continue under Flerie AB, with Toleranzia's pipeline expected to benefit from broader ownership and resources.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Toleranzia
- Toleranzia submitted its TOL2 trial application and secured major warrant funding commitments.TOL
Q3 2024 - Operating losses narrowed as TOL2 nears clinical trials and financing options strengthen.TOLQ2 2024
- Q1 2025 saw Toleranzia advance TOL2 and pursue a merger amid urgent funding needs.TOLQ1 2025
- TOL2 clinical trial approved, SEK 37M raised, and full-year loss at KSEK -10,248.TOLQ4 2024
Toleranzia
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Toleranzia AB is a biotechnology company specializing in the development of protein-based drugs for the treatment of autoimmune diseases. The company leverages its proprietary platform to create therapeutic proteins aimed at inducing immune tolerance in patients, addressing the underlying causes of autoimmune conditions rather than merely alleviating symptoms. Toleranzia focuses on diseases with significant unmet medical needs, striving to provide innovative treatments that can improve patients' quality of life. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Stockholm Stock Exchange.